Roflumilast topical foam receives FDA approval for treating seborrheic dermatitis
USA: Roflumilast topical foam, 0.3% has received approval from the US Food and Drug Administration (FDA), for the treatment of seborrheic dermatitis in those aged 9 years and older. The approval has been granted to Arcutis Biotherapeutics, Inc. Seborrheic dermatitis affects more than 10 million individuals in the US. ZORYVE foam provides rapid disease clearance […]